Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-22T22:34:52.546Z Has data issue: false hasContentIssue false

P.165 Surgery for recurrent GBM: deciding when to operate

Published online by Cambridge University Press:  05 January 2022

MR Voisin
Affiliation:
(Toronto)*
JA Zuccato
Affiliation:
(Toronto)
G Zadeh
Affiliation:
(Toronto)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Previous studies have found conflicting results regarding the role of repeat surgery on overall survival (OS) in patients with GBM. We used a novel approach that includes time to tumour recurrence as an additional prognostic factor in order to determine which patients benefit most from repeat surgery. Methods: A retrospective chart review from 1992-2018 was performed on all adult (≥ 18 years old) patients with primary GBM that received surgery for recurrent disease and compared to publicly available data from The Cancer Genome Atlas (TCGA) of adult patients with primary GBM that did not undergo surgery for recurrent disease. Results: A total of 672 adult patients with GBM were included in the study, including 87 that received surgery at tumour recurrence (surgery cohort). The surgery cohort had longer OS and similar complication rates to those that did not receive surgery at recurrence, independent of time to tumour recurrence (p < 0.0001 and p = 0.4, respectively). Within the surgery cohort, patients with tumour recurrence >6 months demonstrated additional survival benefit (p < 0.0001). Conclusions: Surgery for recurrent GBM leads to improved survival without increased complications. Patients with tumour recurrence >6 months benefit most from repeat surgery.

Type
Poster Presentations
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation